Fasudil

CARDIOVASCULAR SYSTEM

Key facts

Fasudil is a drug catalogued in DrugCentral. It was first approved by the PMDA in 1995. DrugCentral lists 24 molecular targets, including ROCK2, PKN3 and ROCK1. Recorded indications include Cerebral ischemia and Spasm of cerebral arteries.

• Molecular targets: ROCK2, PKN3, ROCK1 and CLK1 (24 listed in DrugCentral).
• Indications: Cerebral ischemia and Spasm of cerebral arteries.
• ATC code: C04AX32 (Other peripheral vasodilators).
• Molecular formula: C14H17N3O2S; molecular weight 291.38 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Cerebral ischemia
• Spasm of cerebral arteries

Mechanism & targets

Molecular targets (24)

Target	Gene	Action	Activity
Rho-associated protein kinase 2	ROCK2	inhibitor	Kd 7.11
Serine/threonine-protein kinase N3	PKN3	unknown	Kd 7.00
Rho-associated protein kinase 1	ROCK1	inhibitor	Ki 7.00
Dual specificity protein kinase CLK1	CLK1	unknown	Kd 6.82
Serine/threonine-protein kinase N2	PKN2	unknown	IC50 6.11
cAMP-dependent protein kinase catalytic subunit alpha	PRKACA	unknown	AC50 5.81
Serine/threonine-protein kinase N1	PKN1	unknown	IC50 5.77
Maternal embryonic leucine zipper kinase	MELK	unknown	Kd 5.72
Rho-associated protein kinase 2	Rock2	unknown	IC50 5.72
Ribosyldihydronicotinamide dehydrogenase [quinone]	NQO2	unknown	Kd 5.61
Protein kinase C epsilon type	PRKCE	unknown	IC50 5.52
Cyclin-dependent kinase 12	CDK12	unknown	Kd 5.46
Serine/threonine-protein kinase LATS1	LATS1	unknown	Kd 5.38
Cyclin-dependent kinase 9	CDK9	unknown	Kd 5.37
Cyclin-dependent kinase 13	CDK13	unknown	Kd 5.34
Protein kinase C delta type	PRKCD	unknown	Kd 5.32
Ribosomal protein S6 kinase alpha-5	RPS6KA5	unknown	IC50 5.30
Serine/threonine-protein kinase D2	PRKD2	unknown	Kd 5.19
C-C motif chemokine 2	CCL2	unknown	IC50 5.16
Serine/threonine-protein kinase D3	PRKD3	unknown	Kd 4.63

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1995-06-30	PMDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C04AX32	CARDIOVASCULAR SYSTEM › PERIPHERAL VASODILATORS › PERIPHERAL VASODILATORS › Other peripheral vasodilators

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Fasudil is on its molecule page.

• Molecular formula: C₁₄H₁₇N₃O₂S
• Molecular weight: 291.38 g/mol
• CAS number: —
• InChIKey: NGOGFTYYXHNFQH-UHFFFAOYSA-N
• PubChem CID: 3547

O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Fasudil used for?

DrugCentral lists the following indications for Fasudil: Cerebral ischemia and Spasm of cerebral arteries.

How does Fasudil work?

Its molecular targets in DrugCentral include ROCK2 (inhibitor), PKN3, ROCK1 (inhibitor) and CLK1.

When was Fasudil first approved?

Fasudil was first approved by the PMDA in 1995.

What is the chemical formula of Fasudil?

Fasudil has the molecular formula C14H17N3O2S and a molecular weight of 291.38 g/mol.

Sources

• DrugCentral drug card 1132 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL38380 — compound record and bioactivity
• PubChem CID 3547 — chemical identifiers
• DrugBank DB08162 — drug record
• FDA UNII Q0CH43PGXS — substance identity
• UniProt O75116 (ROCK2) — target protein
• UniProt Q6P5Z2 (PKN3) — target protein
• UniProt Q13464 (ROCK1) — target protein
• UniProt P49759 (CLK1) — target protein
• UniProt Q16513 (PKN2) — target protein
• UniProt P17612 (PRKACA) — target protein

How this page is built: methodology · editorial policy & corrections.